← All trials
NCT05656508
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 20, 2022
- Primary completion
- Sep 30, 2022
- Completion date
- Jun 29, 2023
- First posted
- Dec 19, 2022
- Last posted
- Dec 23, 2022
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Laboratorio Pablo Cassará S.R.L.Lead sponsor
- National Council of Scientific and Technical Research, ArgentinaCollaborator
- Universidad Nacional de San Martín (UNSAM)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.